- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 217
- Founded in 2016
- Headquartered in San Francisco, California
- http://www.vir.bio
Vir Biotechnology confirms comments made during interviews; Company is in discussions with manufacturers and regulators regarding expediting the manufacture and regulatory pathway for any potential therapy
On January 29, 2020, Dr. George Scangos, President and Chief Executive Officer of Vir Biotechnology, provided interviews with several news media outlets to discuss the Company's efforts to develop a therapy for 2019-nCoV, also known as "Wuhan coronavirus". In the interviews, Dr. Scangos discussed the timing of potentially developing a therapy and stated that the Company believes that it will know whether any of its current antibodies are effective against the Wuhan coronavirus in the next weeks to months. Dr. Scangos also disclosed that manufacturing would take an additional number of months, and that the expected process could total approximately 10 months, although actual timelines are difficult to predict. In addition, the Company is in discussions with manufacturers and regulators regarding expediting the manufacture and regulatory pathway for any potential therapy.
No comments:
Post a Comment